Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

Resource Type

CF Research News

Authors

Carsten Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C Klingsberg, Rainald Fischer, Steven M Rowe, Paul K Audhya, Neil Ahluwalia, Xiaojun You, Thomas J Ferro, Margaret E Duncan, Bote G Bruinsma

References

J Cyst Fibros. 2020 Jun 23;S1569-1993(20)30730-X. doi: 10.1016/j.jcf.2020.06.001.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Clinical trial [3]
Phase 3 [4]
Phe508del-CFTR [5]

Date

Tuesday, June 23, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [6]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/tezacaftorivacaftor-people-cystic-fibrosis-who-stopped

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00108R1_FINAL_Schwarz_061020.pdf [2] https://pubmed.ncbi.nlm.nih.gov/32586736/ [3] https://www.ecfs.eu/research-article-keywords/clinical-trial [4] https://www.ecfs.eu/research-article-keywords/phase-3 [5] https://www.ecfs.eu/research-article-keywords/phe508del-cftr [6] https://www.ecfs.eu/resource-guideline-type/other-guidelines